ArticleTranslational pediatrics2026
Weekly pegylated recombinant human growth hormone for prepubertal children with growth hormone deficiency: adherence advantage drives superior short-term efficacy over daily rhGH.
Article in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pediatric growth hormone deficiency (GHD) causes growth retardation due to insufficient pituitary growth hormone (GH) secretion. Conventional daily recombinant human growth hormone (rhGH) has low adherence due to frequent injections, impairing efficacy; weekly pegylated recombinant human growth hormone (PEG-rhGH) may improve adherence, but the mediating role of adherence differences in efficacy remains unclear. This study aimed to compare the 12-month efficacy and safety of weekly PEG-rhGH versus daily rhGH in prepubertal children, and to determine whether objective (injection completion rate) and subjective (Beliefs about Medicines Questionnaire) adherence mediate the efficacy difference. Methods: A single-center retrospective cohort study was conducted in the Department of Endocrine, Genetic, and Immunology, Children's Hospital of Xinjiang Uygur Autonomous Region (January 2020-December 2023). A total of 148 eligible prepubertal GHD children were enrolled, including 85 in the PEG-rhGH group (0.2 mg/kg/week, weekly injection) and 63 in the rhGH group (0.03 mg/kg/day, daily injection). Baseline characteristics were compared between the two groups. Adherence was evaluated by injection completion rate (ICR) (objective) and Beliefs about Medicines Questionnaire (BMQ, subjective). The primary efficacy indicator was 12-month change in height standard deviation score (△Ht-SDS), and the secondary indicator was 12-month height velocity (HV). The Hayes PROCESS macro (5,000 Bootstrap resamplings) was used to test the mediating effect of adherence. Results: There were no significant differences in baseline characteristics between the two groups (all P>0.05). The PEG-rhGH group had significantly higher 12-month total ICR (69.27%±8.60% Conclusions: In prepubertal GHD children, weekly PEG-rhGH has better adherence (objective + subjective) and short-term efficacy (△Ht-SDS, HV) than daily rhGH, with comparable safety. Adherence is the core mediating factor for the efficacy difference between the two regimens, providing a better treatment option for children with poor adherence to daily rhGH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.